Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04892017 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, sponsored by Deciphera Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 10
- Study locations
NCT04892017: Active Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, sponsored by Deciphera Pharmaceuticals.
NCT04892017 is a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor that is active but no longer recruiting, run by Deciphera Pharmaceuticals. The registered enrollment target is 144 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (78% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04892017, a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, is active but no longer recruiting, sponsored by Deciphera Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 1/2, multicenter, open label, first in human (FIH) study of inlexisertib as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
Primary Outcome
Identify the observed adverse events, serious adverse events associated with inlexisertib as monotherapy and in combination with trametinib, binimetinib, or sotorasib.
Conditions Studied
Interventions
- DRUG Trametinib
- DRUG Sotorasib
- DRUG Binimetinib
- DRUG Inlexisertib
Study Locations (10)
Texas
- NEXT Oncology - Austin
- The University of Texas MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University Siteman Cancer Center - St Louis
New Jersey
- Rutgers Cancer Institute - New Brunswick
New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
Oregon
- Oregon Health and Science University - Portland
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Wisconsin
- University of Wisconsin Clinical Science Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2021-06-15 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
What the registry record for NCT04892017 still lists
NCT04892017 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (78% lower).
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Trametinib is the first listed.
NCT04892017 lists 10 locations in 8 states (Texas, Massachusetts, Missouri).
Frequently Asked Questions
What is clinical trial NCT04892017 about?
NCT04892017 is a clinical study titled "A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors". This is a Phase 1/2, multicenter, open label, first in human (FIH) study of inlexisertib as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation...
What is the current status of trial NCT04892017?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2021-06-15. Estimated completion is 2028-08.
What conditions does trial NCT04892017 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor.
What interventions are being tested in trial NCT04892017?
The interventions under investigation include: Trametinib (DRUG), Sotorasib (DRUG), Binimetinib (DRUG), Inlexisertib (DRUG).
Who is sponsoring clinical trial NCT04892017?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04892017 being conducted?
This trial has 10 study locations across Massachusetts, Missouri, New Jersey, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04892017's enrollment target sits among peer trials
144 203rd of 454 higher than 252 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI